Nurix Therapeutics, Inc. 4

Chief Legal Officer Christine Ring of Nurix Therapeutics, Inc. exercised 5,787 options at $8.72 and sold 5,787 common shares around $25.70–$26.64, ending with 9,110 shares owned directly.

On September 2, 2026, Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised 5,787 stock options at $8.72 per share, acquiring 5,787 shares of common stock, and on the same day sold an aggregate 5,787 shares of common stock in two open market transactions under a Rule 10b5-1 trading plan: 5,387 shares at a weighted average price of $25.6947 and 400 shares at a weighted average price of $26.6375. The option exercise was reported as an acquisition, increasing her direct holdings to 14,897 shares before the sales, after which her direct ownership stood at 9,110 shares, implying an estimated post-transaction holding value of about $234,000 based on the reported sale prices. The transactions appear to be a routine option exercise followed by partial monetization rather than a net new economic purchase of shares.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817199-26-000030

Alert Tier

6